The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.
![The Request Failed due to a Fatal Device Hardware Error [2025 Lastest]](https://lbnntv.com/wp-content/uploads/2025/07/The-Request-Failed-due-to-a-Fatal-Device-Hardware-Error-120x86.png)
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.
